anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sarcoidosis is a systemic granulomatous disease of unknown cause, most commonly affecting the lungs, which tends to afflict young adults in the prime of their lives. Recent data indicating that sarcoidosis mortality rates are rising in the U.S. (1) and Europe (2) highlight the inadequacy of current therapies. As noted in a recent NIH-sponsored sarcoidosis workshop, the lack of relevant animal, computer or in vitro models represents a bottleneck for progress towards understanding disease mechanisms and developing highly effective sarcoidosis treatments (3). The lack of useful disease models likely contributes to the current lack (zero) of investigator-initiated (RO1) projects supporting sarcoidosis research.

The long-term goal of this proposal is to develop a novel human sarcoidosis research model to fill the current void in the field, thereby expediting exploration of basic disease mechanisms and pre-clinical testing of novel therapies. The objective of this application, which is the first step towards achieving the long-term goal, is to develop a novel in vitro human granuloma model to represent abnormal granuloma formation in the context of sarcoidosis. In this regard, a growing body of evidence indicates that mycobacterial antigens are commonly harbored in sarcoidosis tissues, to which these patients are sensitized (4, 5). Our central hypothesis is that the pathological mechanisms of sarcoidosis can be modeled in vitro, as represented by abnormal granuloma formation in response to mycobacterial and other ubiquitous environmental antigens. The feasibility of our proposed model is supported by preliminary studies showing that subjects sensitized to Mycobacterium tuberculosis antigens (latent TB tuberculosis with a positive TB skin test) form well-organized granulomas readily in response to challenge with TB antigens, compared to healthy controls. This project is highly innovative and we feel has an excellent likelihood of leading to a critical breakthrough in the field of sarcoidosis research.
Pain is a major non-motor symptom of Parkinson's disease (PD). Alterations in the descending pain inhibitory system (DPIS) have been reported to trigger hyperalgesia in PD patients. However, the underlying mechanisms remain unclear. In the current study, dopaminergic nigrostriatal lesions were induced in rats by injecting 6-hydroxydopamine (6-OHDA) into their medial forebrain bundle. The neural mechanisms underlying changes in nociception in the orofacial region of 6-OHDA-lesioned rats was examined by injecting formalin into the vibrissa pad. The 6-OHDA-lesioned rats were seen to exhibit increased frequency of face-rubbing and more c-Fos immunoreactive (c-Fos-IR) cells in the trigeminal spinal subnucleus caudalis (Vc), confirming hyperalgesia. Examination of the number of c-Fos-IR cells in the DPIS nuclei [including the midbrain ventrolateral periaqueductal gray, the locus coeruleus, the nucleus raphe magnus, and paraventricular nucleus (PVN)] showed that 6-OHDA-lesioned rats exhibited a significantly lower number of c-Fos-IR cells in the magnocellular division of the PVN (mPVN) after formalin injection compared to sham-operated rats. Moreover, the 6-OHDA-lesioned rats also exhibited significantly lower plasma oxytocin (OT) concentration and percentage of oxytocin-immunoreactive (OT-IR) neurons expressing c-Fos protein in the mPVN and dorsal parvocellular division of the PVN (dpPVN), which secrete the analgesic hormone OT upon activation by nociceptive stimuli, when compared to the sham-operated rats. The effect of OT on hyperalgesia in 6-OHDA-lesioned rats was examined by injecting formalin into the vibrissa pad after intracisternal administration of OT, and the findings showed a decrease in the frequency of face rubbing and the number of c-Fos-IR cells in the Vc. In conclusion, these findings confirm presence of hyperalgesia in PD rats, potentially due to suppression of the analgesic effects of OT originating from the PVN.
FIELD: medicine. ^ SUBSTANCE: there are offered versions of a monoclonal antibody specific to GPVI polypeptide, peptide or its naturally occurred version. A based antithrombotic composition and a method for preparing thereof are described. The versions of methods for inhibition and treatment of various thrombocyte aggregation mediated diseases are disclosed. An antithrombotic set and hybridoma for producing the monoclonal antibody are described. ^ EFFECT: use of the invention provides the antibodies inhibiting thrombocyte aggregation that can find the further application in medicine for treating various thromboses. ^ 13 cl, 16 dwg, 9 tbl, 10 ex
Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
Serious events of hypercalcemia requiring hospitalization have been reported with YORVIPATH. The risk is highest when starting or increasing the dose of YORVIPATH but may occur at any time. Measure serum calcium 7 to 10 days after any dose change or if there are signs or symptoms of hypercalcemia, and at a minimum of every 4 to 6 weeks once the maintenance dose is achieved. Treat hypercalcemia if needed. If albumin-corrected serum calcium is greater than 12 mg/dL, withhold YORVIPATH for at least 2-3 days [see Dosage and Administration (2.4)]. For less serious hypercalcemia, adjust the dose of YORVIPATH, active vitamin D, and/or calcium supplements [see Dosage and Administration (2), Adverse Reactions (6.1)].
The efficacy and safety of hypertonic saline (HS) in CF patients over 6 years of age has been demonstrated in clinical trials of 2 to 48 weeks' duration. Based on these results, a large randomized, placebo-controlled trial of the efficacy and safety of 7% HS administered twice daily for 48 weeks to infants with CF, 4 to 15 months of age at enrollment, is planned (the Infant Study of Inhaled Saline (ISIS) trial). It is anticipated that 150 infants at up to 16 sites will be enrolled in the ISIS trial.

To date, the only evaluations of the safety of HS in infants with CF have been small single-dose studies. There has been no evaluation of the tolerability of chronic HS administration. The goal of this study is to assess the safety and tolerability of exposure to 14 days of 7% HS administered twice daily in infants with CF, prior to enrolling subjects in the planned large, randomized, controlled trial. Conduct of this study will provide evidence for the tolerability of chronic HS administration in infants with CF and estimates of the proportion of infants who do not tolerate chronic HS treatment. The results will be used to establish the appropriate measures of tolerability at enrollment in the ISIS trial, and to refine sample size estimates to account for withdrawal due to intolerance of HS.
A piperidine derivative, and a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. A compound of the piperidine derivative is as shown in formula (I), and definitions of substituents are detailed in the description. The piperidine derivative can be used as a bifunctional selective ligand for a ?(mu)-opioid peptide receptor (MOPR) and a ?(kappa)-opioid peptide receptor (KOPR), or a bifunctional selective ligand for a MOPR and a nociceptin opioid peptide receptor (NOPR)/opioid receptor like-1 (ORL-1) receptor. Such a compound or a pharmaceutical composition thereof can be used for treating pain, anxiety, depression, alcohol addiction, and substance abuse/dependence.
Acute hemodynamic compromise after transcatheter aortic valve replacement (TAVR) because of dynamic left ventricle (LV) obstruction (LVO), also known as suicide LV, is an infrequent but severe complication of TAVR that is poorly defined in previous studies. Understanding this complication is essential for its prompt diagnosis and optimal treatment. We conducted a systematic literature review using PubMed, Embase, Web of Science, and Medline databases for studies describing acute hemodynamic compromise after TAVR because of dynamic LVO or suicide LV. Each study was reviewed by 2 authors individually for eligibility, and a third author resolved disagreements. From a total of 506 studies, 25 publications were considered for the final analysis. The majority of patients with this condition were women demonstrating a hypertrophic septum, a small ventricle, and hyperdynamic contractility on pre-TAVR echocardiographic assessment. An intraventricular gradient before TAVR was found in half of the cases. Acute hemodynamic compromise after TAVR because of dynamic LVO manifested mainly as significant hypotension and occurred most often immediately after valve deployment. The LV outflow tract was the most common site of obstruction. Advanced therapies were required in nearly 65% of the cases. In conclusion, acute hemodynamic compromise after TAVR because of dynamic LVO occurred almost invariably in women. Echocardiography before TAVR may offer essential information to anticipate this complication. LV outflow tract obstruction appears to carry the highest risk of developing this phenomenon. Advanced therapies should be promptly considered as a bailout strategy in patients with hemodynamic collapse refractory to medical therapy.
1356449 Extracts of edible fungi C IIZUKA and C FUMOTO 23 July 1971 [30 Dec 1970 17 May 1971 30 June 1971[ 34644/71 Heading A5B The water-soluble components of the hyphae of an edible fungus useful in the treatment of high blood pressure, tonsilitis, colds, vesicular eczema and stomach cancer, are extracted by cultivating the hyphae of the edible fungus (preferably shiitake) in a prepared culture medium comprising one or more solid nutrients for the edible fungus such as bagasse, sawdust, log and/or rice bran, reducing the hyphae and the culture medium to fine particles approximately at the time when the hyphae begin fruiting, forming an aqueous suspension of the fine particles, and filtering the suspension to remove undesirable matter therefrom and to provide an aqueous solution of an extract of the edible fungus. The hyphae culture may be subjected to a rapid reduction in temperature and/or a change in humidity such as to accelerate the growth of the hyphae, e.g. the culture is reduced from room temperature to from 4‹C to 8‹C and, after being maintained at the reduced temperature for a period of time, the culture is immersed in water at 5‹C. The suspension may be heated in a sealed vessel, before being filtered, to a temperature at which the production of enzymes in the hyphae is accelerated; preferably the suspension is heated first to from 30‹C to 35‹C for one hour and then to from 45‹C to 55‹C for one to two hours. The aqueous extract obtained may be admixed with ammonium sulphate so as to precipitate the substances contained in the extract, the precipitate is collected, dissolved in water and the resulting solution is dialyzed to remove any remaining ammonium sulphate. The extract contains enzymes including #-1-3 gluconase and chitinase, amino acids, vitamins, ergosterin, polysaccharides and polypeptides.
Patients in the intervention group will receive an oral preparation of 50 grams of Maltodextrin solution mixed in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.
Investigate one acute bout of exercise on the brain insulin responsiveness using functional magnetic resonance imaging in combination with intranasal insulin in healthy participants of normal-weight and overweight/obesity. Two single endurance exercise sessions with different intensities will be evaluated, namely moderate intensity continuous training (MICT) and high-intensity interval training (HIIT). This will be compared to a waiting control condition. In a cross-over design, investigators will compare cerebral response from before to after intranasal insulin administration after a single bout of HIIT or MICT compared to a control condition without exercise. Cerebral response is defined as the cerebral blood flow and resting state functional connectivity in response to intranasal insulin. Secondary outcomes include changes in blood metabolites and proteins and changes in eating behavior.
Supporting families experiencing critical illness through family interventions is essential to ease illness burden, enable family management, and reduce their risk for adverse health. Thus far, there is no validated German instrument to measure the perceived support families receive from nurses. We translated the 14-item Iceland-Family Perceived Support Questionnaire (ICE-FPSQ) and tested its psychometric properties with 77 family members of intensive care patients. Compared with the original instrument, the construct validity of the German ICE-FPSQ (FPSQ-G) showed unstable results with a partially divergent structure, most likely caused by the limited sample size. The first two principal components explained 61% of the overall variance and a good internal consistency with a Cronbach's alpha of .92. The FPSQ-G is a promising instrument to measure family members' perceptions of the support they received from nurses in the acute critical care setting but requires further validation.
PROBLEM TO BE SOLVED: To obtain an active oxygen eraser and skin cosmetic having keratinization-promoting effect and excellent active oxygen erasing effect and capable of effectively improving or preventing aging of skin and pigmentation by synergism thereof by including an extract of a specific plant of the family Compositae therein. SOLUTION: This active oxygen eraser or skin cosmetic comprises (A) an extract obtained from Centipeda minima. A material obtained by drying whole grass of Centipeda minima or directly using the fresh plant or cutting the plant and extracting the plant in an mount of 5-50 pts.wt. expressed in terms of dried material with 100 pts.wt. extracting solvent such as water is preferable as the component A. The component A is preferably formulated in an amount of 0.00001-10.0 wt.% expressed in terms of dried material based on total amount with the active oxygen eraser or skin cosmetic. An active oxygen eraser or skin cosmetic having epidermis keratinization-promoting effect as well as active oxygen erasing effect and lipoperoxide production-suppressing effect and excellent in skin aging-preventing effect and excellent in use for bleaching can be provided thereby.
A predetermined portion of medicament (5) fills an open-topped cup (4) brought close to a heat source, raising its contents to no more than 60-80 deg C. The contents separate to water, grease and volatile oils which float on top. Heating continues until the oils have been volatilized into the surroundings. The vapors may be inhaled in-situ. Preferred Process: The surface temperature of the hotplate (1) used, reaches 100-110 deg C, spaced within 0.8-1.2 mm of the cup base. Cup contents are heated to about 78 deg C. About 2 grams of medicament are heated in the cup for about 8 hours. The medicament contains about 22%-40% of volatile oil. The cup is made of heat resistant plastic, its diameter 16 mm, height 15-20 mm and base thickness about 0.8-1.2 mm.
FIELD: medicine. SUBSTANCE: composition has at least two of the following separately produced extractions from vegetable raw materials selected from a group composed of Bryonia, Ipecacuanha, Drosera in the amount of at least 75% by mass. The composition additionally has antimony or potassium tartrate in the amount of up to 25% by mass. The method involves washing and cleaning the vegetable raw materials of Bryonia, Ipecacuanha, Drosera, superficial sterilization of the mentioned vegetable raw materials with sodium hypochlorite and drying. The dried vegetable raw materials are separately cut in small pieces, separately crushed and atomized with desirable particle size being equal to 1 mm. Individual The vegetable raw materials are extracted with polar and the solvent is evaporated in vacuum for producing the material as powder. Mixing at least one of the mentioned preparations and optionally antimony and sodium tartrate in 100-75:0-25 is carried out. EFFECT: enhanced effectiveness of treatment; high accuracy in preparing composition. 20 cl, 19 tbl
ERAS-601 will be administered in sequential ascending doses with pembrolizumab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or non small cell lung cancer (NSCLC).
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to oncology and can be used for treatment of locally spread resectable esophageal cancer. Method includes radical surgery, polychemotherapy and radiotherapy. Before operation 2 courses of polychemotherapy are carried out in accordance with the scheme: cysplatin 50 mg/m2 1,8 day, gemcitabine -800 mg/m2 intravenously drop-by-drop during half-hour infusion - 2, 9 days with 3-week long interval between courses. After that, surgical intervention in radical volume with two-zonal 2F lymphodissection, with carrying out IORT in single dose 10 Gy onto the bed of removed tumour and ways of regional metastasis. In post-operational period additionally course of DGT is carried out on cervical, supraclavicular zones in TFD -40 Gy. ^ EFFECT: application of invention makes it possible to increase efficiency of combined treatment due to prevention of tumour process progression and distant metastasis and reduction of number of post-operational complications. ^ 1 ex
Patients randomized (1:1) to the placebo arm will receive an initial intravenous infusion of saline for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
This mechanistic study will utilise a within-subjects design, administering up to 10mg of psilocybin to participants with OCD (DSM-5 criteria) on two separate instances spaced four weeks apart. To ensure consistency and participant safety, dosing will occur under medical supervision with psychological support from two experienced therapists. Before and after each session, participants will engage in virtual preparation and integration sessions led by their therapists. Cognitive tasks will be administered in the days following each dosing session. Additionally, acute post-dosing EEG recordings will be conducted, and blood samples will be taken after each dosing session. OCD symptoms will also be assessed seven times throughout the trial by an external blinded psychiatrist, serving as a secondary outcome. Collectively, these measures aim to evaluate changes in cognitive inflexibility, decision-making abilities, neuroplasticity (peripheral blood markers and EEG measures), inflammation (peripheral blood markers), and symptomatology following each dosing session.
BACKGROUND: Multiple studies have confirmed that programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) is widely expressed in gestational trophoblastic neoplasia (GTN) tissues. Therefore, immune checkpoint inhibitors may be an option for the treatment of recurrent and drug-resistant GTN.
CASE: Four patients with recurrent or drug-resistant GTN who were treated with PD-1/PD-L1 checkpoint inhibitor agents combined with chemotherapy were reported. The mean age of recurrence was 45.8 years (35-56 years), including three cases of choriocarcinoma (CC) and one case of invasive mole (IM). International Federation of Gynecology and Obstetrics (FIGO) prognosis score: ≤6 (low risk) in one case, 7-12 (high risk) in one case, ≥13 (very high risk) in two cases. There were two cases of lung metastasis and one case of vulvar and inguinal lymph node metastasis. One of the four patients underwent total hysterectomy and one patient underwent resection of lung metastases. All the four patients received comprehensive treatment of immunotherapy combined with chemotherapy after relapse, among which one patient achieved complete response (CR), two patients achieved partial response (PR), and one patient developed progressive disease (PD). Three patients who achieved PR or CR were maintained by single agent immunotherapy after combination therapy, and there was no disease recurrence during follow-up. One patient with PD also achieved CR after using salvage chemotherapy after recurrence, and there was no disease recurrence during follow-up. During the treatment, four patients had different degrees of immune-related adverse reactions, all of which were grade I-II, and no severe adverse reactions were found.
CONCLUSION: Immune checkpoint inhibitors combined with chemotherapy has an impressive therapeutic effect on recurrent or drug-resistant GTN with mild adverse reactions, which can be used as a treatment option for such patients. However, due to the lack of large sample data support, the specific time and treatment course of its use, long-term use of adverse reactions and whether it affects fertility function remain to be solved.
FIELD: medicine. SUBSTANCE: method involves preparing the ether concentrate containing mint oil and one or some oils from the following order: fennel, caraway, anise, dill, coriander, bergamot, nutmeg-sage, rose, lavender, lemon, orange, eucalyptus and ylang-ylang oil. Oily extract of plant raw is prepared that contains wormwood herb, peppermint leaves, Saint-John's-wort herb and other wound-healing and antiseptic plant raw. Oily extract is prepared by extraction of each component or mixture in medium of organic solvent or liquid gas followed by removing the extractant. The obtained extracts were filtered, combined and diluted with food vegetable oil. Ether concentrate, oily extract and camphor were mixed at the following ratio of components, wt.-%: camphor 0.3 (not less); ether concentrate 0.3 (not less), and oily extract - the rest. EFFECT: improved method of preparing. 1 tbl